bluebird bio’s (BLUE) Hold Rating Reiterated at Jefferies Group LLC

Jefferies Group LLC restated their hold rating on shares of bluebird bio, Inc. (NASDAQ:BLUE) in a research report report published on Friday, November 3rd. Jefferies Group LLC currently has a $130.00 price objective on the biotechnology company’s stock. Jefferies Group also issued estimates for bluebird bio’s Q4 2017 earnings at ($1.71) EPS, FY2017 earnings at ($6.85) EPS, FY2018 earnings at ($7.26) EPS, FY2019 earnings at ($7.01) EPS, FY2020 earnings at ($4.19) EPS and FY2021 earnings at $4.38 EPS.

Several other research firms have also recently issued reports on BLUE. BidaskClub raised shares of bluebird bio from a sell rating to a hold rating in a research report on Wednesday, August 9th. Morgan Stanley reaffirmed a hold rating on shares of bluebird bio in a research report on Wednesday, August 9th. Leerink Swann reaffirmed an outperform rating and set a $120.00 price objective on shares of bluebird bio in a research report on Saturday, September 30th. BMO Capital Markets reissued a buy rating and issued a $108.00 price target on shares of bluebird bio in a research report on Friday, August 4th. Finally, Cantor Fitzgerald reissued a sell rating and issued a $39.00 price target on shares of bluebird bio in a research report on Monday, July 24th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and fourteen have issued a buy rating to the company’s stock. bluebird bio currently has an average rating of Buy and an average price target of $131.05.

Shares of bluebird bio (BLUE) opened at $167.20 on Friday. bluebird bio has a 1-year low of $56.80 and a 1-year high of $169.60.

bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.68) by ($0.05). The business had revenue of $7.71 million during the quarter, compared to analyst estimates of $8.47 million. bluebird bio had a negative return on equity of 28.79% and a negative net margin of 883.18%. The business’s revenue was up 397.4% on a year-over-year basis. During the same quarter last year, the firm earned ($2.07) EPS. equities analysts anticipate that bluebird bio will post -6.68 earnings per share for the current year.

WARNING: “bluebird bio’s (BLUE) Hold Rating Reiterated at Jefferies Group LLC” was first posted by BBNS and is owned by of BBNS. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://baseballnewssource.com/markets/bluebird-bio-inc-blue-stock-rating-reaffirmed-by-jefferies-group-llc/1757197.html.

In other bluebird bio news, CEO Nick Leschly sold 10,823 shares of the stock in a transaction that occurred on Tuesday, October 17th. The shares were sold at an average price of $145.05, for a total transaction of $1,569,876.15. Following the transaction, the chief executive officer now owns 262,409 shares of the company’s stock, valued at $38,062,425.45. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Daniel Lynch sold 500 shares of the stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $120.00, for a total transaction of $60,000.00. Following the transaction, the director now directly owns 3,300 shares in the company, valued at approximately $396,000. The disclosure for this sale can be found here. Insiders have sold 193,168 shares of company stock worth $25,558,003 in the last three months. Insiders own 3.90% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the company. FMR LLC increased its position in shares of bluebird bio by 9.6% in the second quarter. FMR LLC now owns 6,713,949 shares of the biotechnology company’s stock worth $705,301,000 after acquiring an additional 587,236 shares in the last quarter. Capital Research Global Investors increased its position in shares of bluebird bio by 9.9% in the second quarter. Capital Research Global Investors now owns 5,483,117 shares of the biotechnology company’s stock worth $576,001,000 after acquiring an additional 493,072 shares in the last quarter. Baillie Gifford & Co. grew its holdings in bluebird bio by 3.8% during the 2nd quarter. Baillie Gifford & Co. now owns 5,400,658 shares of the biotechnology company’s stock valued at $567,339,000 after purchasing an additional 196,025 shares in the last quarter. Vanguard Group Inc. grew its holdings in bluebird bio by 10.7% during the 2nd quarter. Vanguard Group Inc. now owns 3,559,102 shares of the biotechnology company’s stock valued at $373,884,000 after purchasing an additional 343,856 shares in the last quarter. Finally, BlackRock Inc. grew its holdings in bluebird bio by 4.3% during the 2nd quarter. BlackRock Inc. now owns 3,320,329 shares of the biotechnology company’s stock valued at $348,801,000 after purchasing an additional 138,141 shares in the last quarter.

About bluebird bio

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Analyst Recommendations for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Manny Machado Could Change Positions or Uniforms
Manny Machado Could Change Positions or Uniforms
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan


Leave a Reply

 
© 2006-2017 BBNS.